Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ALG1 like 12, pseudogene (ALG1L12P) is classified as a **pseudogene**, meaning it is a genomic sequence similar to a known gene (in this case, related to the ALG1 gene family) but is non-functional and does not produce a protein product[1][5]. Pseudogenes such as ALG1L12P usually lack protein-coding capability due to mutations or truncations, and are not considered therapeutic targets like receptors, enzymes, or transporters[1][5]. While some pseudogenes may have regulatory roles (for example, acting as noncoding RNAs involved in gene expression regulation or disease modulation), there is currently no evidence that ALG1L12P itself has defined biological functions, disease associations, or drug interactions[1][2][5]. There are no drugs, biomarkers, or established safety concerns specifically related to ALG1L12P. As such, it is not a valid therapeutic target, and the entry should be flagged as non-functional/pseudogene rather than a conventional drug target[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ALG1 like 12, pseudogene (ALG1L12P).